| 5.28 1.03 (24.24%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.52  |
1-year : | 7.62 |
| Resists | First : | 5.59 |
Second : | 6.52 |
| Pivot price | 2.62 |
|||
| Supports | First : | 2.43 |
Second : | 0.49 |
| MAs | MA(5) : | 3.74 |
MA(20) : | 2.24 |
| MA(100) : | 1.14 |
MA(250) : | 0.97 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 90.6  |
D(3) : | 91.4 |
| RSI | RSI(14): 94.4 |
|||
| 52-week | High : | 5.59 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BSGM ] has closed above the upper band by 14.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 519.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 18 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.59 - 5.61 | 5.61 - 5.63 |
| Low: | 3.92 - 3.94 | 3.94 - 3.95 |
| Close: | 5.25 - 5.28 | 5.28 - 5.31 |
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Fri, 23 May 2025
BioSig Technologies, Inc. Signs Definitive Share Exchange Agreem - GuruFocus
Fri, 23 May 2025
Biosig Technologies Announced Streamex To Become Wholly Owned Subsidiary Of Biosig - marketscreener.com
Fri, 23 May 2025
BioSig Technologies, Inc. Signs Definitive Share Exchange - GlobeNewswire
Fri, 23 May 2025
BioSig's Massive Pivot: From Medical Tech to $142T Commodity Tokenization Leader with Streamex Deal - Stock Titan
Wed, 21 May 2025
BioSig Technologies Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView
Tue, 20 May 2025
Biosig Tech stock hits 52-week high at $3.08 amid growth - Investing.com Nigeria
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 1.867e+007 (%) |
| Held by Institutions | 17.7 (%) |
| Shares Short | 462 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.242e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 100 % |
| Return on Equity (ttm) | -597.1 % |
| Qtrly Rev. Growth | 40000 % |
| Gross Profit (p.s.) | 415 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 2e+006 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.18 |
| Dividend | 0 |
| Forward Dividend | 448290 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|